138 related articles for article (PubMed ID: 2771996)
1. Pathologic and structural changes in the bladder after BCG intravesical therapy in men.
Pagano F; Bassi P; Milani C; Dalla Palma P; Rebuffi AG; Poletti A; Parenti A
Prog Clin Biol Res; 1989; 310():81-91. PubMed ID: 2771996
[No Abstract] [Full Text] [Related]
2. When is a cystectomy necessary in carcinoma in situ?
Herr HW
Prog Clin Biol Res; 1989; 303():511-5. PubMed ID: 2780659
[No Abstract] [Full Text] [Related]
3. Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.
Reitsma DJ; Guinan P; Lamm DL; Khanna OP; Brosma SA; DeKernion JB; Williams RD; Sipmson G; Hanna MG
Prog Clin Biol Res; 1989; 310():171-85. PubMed ID: 2672014
[No Abstract] [Full Text] [Related]
4. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
[No Abstract] [Full Text] [Related]
5. Immunopathological effects of intravesical BCG therapy.
Prescott S; James K; Hargreave TB; Chisholm GD; Smyth JF
Prog Clin Biol Res; 1989; 310():93-105. PubMed ID: 2672025
[No Abstract] [Full Text] [Related]
6. BCG in the management of superficial bladder cancer.
Guinan P; Richardson C; Hanna M; Rubenstein M
Prog Clin Biol Res; 1989; 303():447-53. PubMed ID: 2675002
[TBL] [Abstract][Full Text] [Related]
7. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
Brosman S
Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
[No Abstract] [Full Text] [Related]
8. Intravesical Bacillus Calmette Guerin therapy in patients with superficial bladder tumor.
Steg A; Belas M; Leleu C; Boccon-Gibod L
Prog Clin Biol Res; 1989; 303():375-81. PubMed ID: 2780654
[No Abstract] [Full Text] [Related]
9. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder tumor: experience of 13 cases].
Okuno H; Shirahase T; Kihara Y; Arai Y
Hinyokika Kiyo; 1989 Sep; 35(9):1503-7. PubMed ID: 2816616
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous, oral, or intravesical BCG administration: what is the optimal route?
Lamm DL; Sarodosy MS; DeHaven JI
Prog Clin Biol Res; 1989; 310():301-10. PubMed ID: 2672018
[No Abstract] [Full Text] [Related]
11. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
Jakse G
Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
[TBL] [Abstract][Full Text] [Related]
12. Intravesical BCG therapy in patients with superficial bladder tumors.
Steg A; Belas M; Leleu C; Boccon-Gibod L
Prog Clin Biol Res; 1989; 310():153-60. PubMed ID: 2771990
[No Abstract] [Full Text] [Related]
13. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
14. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
[No Abstract] [Full Text] [Related]
15. Intravesical instillation of BCG in carcinoma in situ of the urinary bladder. EORTC protocol 30861. EORTC-GU Group.
Jakse G
Prog Clin Biol Res; 1989; 310():187-92. PubMed ID: 2771992
[TBL] [Abstract][Full Text] [Related]
16. [Treatment and follow-up of superficial bladder cancer].
Raitanen M
Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
[No Abstract] [Full Text] [Related]
17. Intravesical therapy for superficial bladder cancer.
Malkowicz SB
Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
[TBL] [Abstract][Full Text] [Related]
18. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
[TBL] [Abstract][Full Text] [Related]
19. [Topical BCG therapy of in situ cancer of the urinary bladder].
Mack D; Jakse G
Urologe A; 1987 Jan; 26(1):22-5. PubMed ID: 3576860
[TBL] [Abstract][Full Text] [Related]
20. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
